Stock listing

NASDAQ:PULM Pulmatrix, Inc. Stock

Home listing (NASDAQ) of Pulmatrix, Inc.

Follow Pulmatrix, Inc. into a list and get an email when it puts out news.

Share price · NASDAQ:PULM

$1.27 USD -0.07 (-5.2%)

Close on Nov 20, 2026

Past year -72.8% · daily closes, Nov 20, 2025 – Nov 20, 2026, adjusted for splits
Day range
$1.20 – $1.42 USDNov 20, 2026
Volume
90,740 sharesNov 20, 2026
Market cap
$4.64M USDAt the close on Nov 20, 2026 · price × 3.65M shares outstanding
52-week range
$1.06 – $4.94 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
Traded on an average day
$49,786 USDMedian day 14,000 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026
Pulmatrix, Inc. logo

Prices by listing

ListingLastChangeVolumeOpenHighLowPrevious closePrice from
NASDAQ:PULM · Home$1.27 USD-0.07 (-5.2%)90,740$1.39$1.424$1.20$1.34Close on Nov 20, 2026

Daily closes

Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:PULM · USD, adjusted for splits

DayCloseChange%OpenHighLowVolume
$1.27-0.07-5.2%$1.39$1.424$1.2090,740
$1.34-0.03-2.2%$1.32$1.36$1.305,883
$1.37+0.04+3.0%$1.325$1.37$1.3253,529
$1.33+0.04+3.1%$1.29$1.389$1.2518,361
$1.29-0.01-0.8%$1.27$1.30$1.255,502
$1.30-0.01-0.8%$1.34$1.34$1.229,771
$1.31-0.04-3.0%$1.33$1.365$1.2914,122
$1.35-0.005-0.4%$1.30$1.42$1.309,396
$1.355-0.025-1.8%$1.38$1.46$1.2821,256
$1.38-0.02-1.4%$1.37$1.445$1.329,987
$1.40-0.12-7.9%$1.52$1.52$1.36114,039
$1.52+0.19+14.3%$1.29$1.54$1.06218,269
$1.33-0.07-5.0%$1.32$1.47$1.3055,934
$1.400.000.0%$1.365$1.40$1.3355,486
$1.40-0.015-1.1%$1.41$1.45$1.359,193
$1.415-0.085-5.7%$1.46$1.475$1.315,735
$1.50+0.01+0.7%$1.47$1.535$1.438,245
$1.49+0.05+3.5%$1.52$1.56$1.4268,370
$1.44-0.04-2.7%$1.45$1.48$1.396,397
$1.48+0.06+4.2%$1.40$1.483$1.409,000
$1.42-0.15-9.6%$1.49$1.52$1.4027,700
$1.57+0.14+9.8%$1.40$1.61$1.376130,700
$1.43+0.01+0.7%$1.40$1.44$1.3913,900
$1.42+0.06+4.4%$1.35$1.46$1.3537,200
$1.36-0.05-3.5%$1.42$1.475$1.3515,000
$1.41+0.04+2.9%$1.36$1.485$1.3422,100
$1.37-0.01-0.7%$1.36$1.39$1.3510,000
$1.38-0.05-3.5%$1.40$1.42$1.3632,800
$1.43-0.03-2.1%$1.465$1.509$1.428,600
$1.46-0.067-4.4%$1.47$1.48$1.434,400
$1.527+0.037+2.5%$1.45$1.58$1.4213,100
$1.49+0.06+4.2%$1.46$1.51$1.4311,900
$1.43-0.05-3.4%$1.50$1.58$1.4119,500
$1.48-0.09-5.7%$1.55$1.59$1.45124,100
$1.57+0.03+1.9%$1.59$1.599$1.4815,300
$1.54+0.02+1.3%$1.54$1.55$1.4977,900
$1.52-0.037-2.4%$1.54$1.58$1.508,400
$1.557-0.033-2.1%$1.59$1.63$1.5557,400
$1.59-0.02-1.2%$1.68$1.68$1.54340,100
$1.61-0.06-3.6%$1.64$1.697$1.6011,900
$1.67-0.015-0.9%$1.685$1.72$1.6614,300
$1.685-0.015-0.9%$1.72$1.755$1.6529,500
$1.70+0.02+1.2%$1.77$1.776$1.645113,000
$1.68+0.24+16.7%$1.39$1.68$1.39249,500
$1.44+0.007+0.5%$1.40$1.46$1.3823,000
$1.433+0.033+2.4%$1.40$1.433$1.3814,200
$1.40-0.045-3.1%$1.44$1.44$1.38217,100
$1.445-0.005-0.3%$1.425$1.445$1.413,400
$1.45+0.04+2.8%$1.39$1.47$1.397,500
$1.41-0.05-3.4%$1.44$1.46$1.417,300
$1.46-0.02-1.4%$1.51$1.51$1.4024,500
$1.48+0.085+6.1%$1.49$1.66$1.43328,400
$1.395+0.005+0.4%$1.38$1.412$1.367,400
$1.39+0.03+2.2%$1.36$1.45$1.3620,200
$1.36-0.11-7.5%$1.44$1.46$1.3620,300
$1.47-0.055-3.6%$1.59$1.59$1.4318,400
$1.525+0.055+3.7%$1.525$1.525$1.525900
$1.47-0.04-2.6%$1.45$1.485$1.452,600
$1.51-0.01-0.7%$1.49$1.52$1.4583,300
$1.52-0.005-0.3%$1.50$1.60$1.46714,000
$1.525-0.075-4.7%$1.56$1.56$1.5255,300
$1.60+0.05+3.2%$1.49$1.60$1.4912,200
$1.55+0.055+3.7%$1.43$1.58$1.4316,800
$1.495-0.005-0.3%$1.50$1.55$1.4939,600
$1.50-0.02-1.3%$1.50$1.56$1.5022,200

Splits

3 splits since 2015 · NASDAQ:PULM · every price before a split is adjusted for it

DayRatioWhat
1-for-20Consolidation
1-for-10Consolidation
2-for-5Consolidation
Ticker
NASDAQ:PULM
Asset type
Stock
Sector
Health care
Industry
Biotechnology
Exchange
NASDAQ
Currency
USD

What changed lately

Latest news

All Pulmatrix, Inc. news

Pulmatrix, Inc. on 6ix

Sector
Health care
Industry
Biotechnology
News releases
11 in the last 12 months · 89 in all · newest Nov 17, 2026 · oldest 2019
Decks
38 decks · latest Oct 22, 2026

Where Pulmatrix, Inc. is listed

ListingExchangeCountryCurrency
NASDAQ:PULM · Home listing · This pageNASDAQUnited StatesUSD
LS Exchange:A3DWEELS ExchangeGermanyEUR
Lang & Schwarz:A3DWEELang & SchwarzGermanyEUR
BOATS:PULMBOATSUnited StatesUSD
Frankfurt:2PUFrankfurtGermanyEUR
gettex:2PUgettexGermanyEUR
Dusseldorf:2PUDusseldorfGermanyEUR
Munich:2PUMunichGermanyEUR
Stuttgart:2PUStuttgartGermanyEUR
Tradegate:2PUTradegateGermanyEUR

Valuation

Price/book 3.5× against a median of 1.2×: 7th lowest of 8 Biotechnology companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026

Enterprise value
$3.24M USD
P/E
Loss
EV/sales
No revenue
EV/EBITDA
No depreciation figure on 6ix yet
Price/book
3.5×
Gross margin
No revenue
Operating margin
No revenue
Net margin
No revenue
Debt to equity
0.0×
Beta vs S&P 500
0.33

Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.

CompanyMkt capEVP/EEV/SalesEV/EBITDAP/BNet mgnDebt/EqBeta
Pulmatrix, Inc. · NASDAQ:PULMUS$4.64MUS$3.24Mn/an/an/a3.5×n/a0.0×0.33
Oncodesign Precision Medicine S.A. · EURONEXT:ALOPMUS$5.04MUS$8.61M0.8×30.0×0.9×1.2×n/a1.6×n/a
Patrys Limited · ASX:PABUS$4.96MUS$4.47Mn/a8.2×n/a10.2×−363.7%0.0×n/a
Invex Therapeutics Ltd. · ASX:IXCUS$4.86MUS$2.20Mn/an/an/a1.9×n/a0.0×n/a
Can-Fite BioPharma Ltd. · TASE:CANFUS$4.86M−US$2.14Mn/a−5.3×n/a1.0×n/a0.0×n/a
Zenith Capital Corporation · OTC:ZHCLFUS$4.83Mn/an/an/an/an/an/an/a0.06
NFL Biosciences SA · EURONEXT:ALNFLUS$4.71MUS$5.36Mn/an/an/an/an/an/an/a
TheraCryf PLC · LSE:TCFUS$4.64MUS$2.63Mn/an/an/a1.3×n/a0.0×n/a
AIM ImmunoTech Inc. · AMEX:AIMUS$4.57M−US$937,186n/a−10.3×n/a0.7×n/a0.2×0.66
Tissue Repair Ltd · ASX:TRPUS$4.40MUS$1.24Mn/a3.4×n/a0.8×−958.0%0.0×n/a
Processa Pharmaceuticals, Inc. · NASDAQ:PCSAUS$4.37M−US$175.8Mn/an/an/an/an/an/a1.60
Median of the othersUS$4.77MUS$2.20M0.8×3.4×0.9×1.2×−660.9%0.0×0.66

Team and board

Officers

OfficerRole
Peter LudlumInterim Chief Executive Officer
Rick BatyckyChief Executive Officer
Todd BazemoreChief Operating Officer
Chris Cabell MDSenior Vice President, Head of Clinical Development

Board

DirectorRole
Michael J. HigginsChairman of the PULMATRiX Board of Directors

Events

QuarterResultsShare move
Q3 2026Nov 17, 2026+0.8%
Q2 2026Aug 13, 2026−3.8%
Q1 2026May 19, 2026+0.8%
Q4 2025Feb 26, 2026−6.8%
Q3 2025Oct 16, 2025+1.2%
Q2 2025Aug 6, 2025−6.0%
Q1 2025May 15, 2025+5.9%
Q4 2024Mar 26, 2025 · Before open−2.2%
Q3 2024Nov 7, 2024 · Before open−2.4%
Q2 2024Aug 13, 2024 · Before open+4.8%
All 20 quarters
QuarterResultsShare move
Q1 2024May 10, 2024 · Before open−3.3%
Q4 2023Mar 28, 2024 · Before open+8.0%
Q3 2023Nov 9, 2023 · Before open−3.6%
Q2 2023Aug 10, 2023 · Before open+0.4%
Q1 2023May 12, 2023 · Before open−4.8%
Q4 2022Mar 30, 2023 · Before open−0.8%
Q3 2022Nov 10, 2022 · Before open+3.1%
Q2 2022Aug 10, 2022 · Before open+5.3%
Q1 2022May 12, 2022 · Before open+0.8%
Q4 2021Mar 29, 2022 · Before open+2.0%

Open Events

Decks

DeckKindSlidesDate
Merger or Acquisition (October 2026)Merger or acquisition35 slidesOct 22, 2026
Merger or Acquisition (November 2024)Merger or acquisition33 slidesNov 13, 2024
Investor Presentation (March 2024)Investor deck32 slidesMarch 2024
Investor Presentation (January 2024)Investor deck30 slidesJan 8, 2024
Investor Presentation (July 2023)Investor deck37 slidesJul 11, 2023
Corporate Update (February 2023)Corporate update42 slidesFeb 3, 2023
Investor Presentation (January 2023)Investor deck36 slidesJan 11, 2023
Corporate Update (November 2022)Corporate update31 slidesNov 14, 2022
Investor Presentation (July 2022)Investor deck13 slidesJul 12, 2022
Investor Presentation (May 2022)Investor deck32 slidesMay 12, 2022
All 38 decks
DeckKindSlidesDate
Investor Presentation (March 2022)Investor deck32 slidesMar 29, 2022
Investor Presentation (December 2021)Investor deck33 slidesDec 7, 2021
Investor Presentation (June 2021)Investor deck17 slidesJun 16, 2021
Investor Presentation (May 2021)Investor deck33 slidesMay 13, 2021
Investor Presentation (April 2021)Investor deck33 slidesApr 12, 2021
Investor Presentation (March 2021)Investor deck33 slidesMar 4, 2021
Investor Presentation (December 2020)Investor deck30 slidesDec 2, 2020
Investor Presentation (September 2020)Investor deck30 slidesSep 22, 2020
Investor Presentation (June 2020)Investor deck32 slidesJun 17, 2020
Investor Presentation (April 2020)Investor deck32 slidesApr 24, 2020
Investor Presentation (January 2020)Investor deck31 slidesJan 13, 2020
Investor Presentation (November 2019)Investor deck33 slidesNov 19, 2019
Investor Presentation (August 2019)Investor deck33 slidesAug 22, 2019
Investor Presentation (August 2018)Investor deck30 slidesAug 1, 2018
Investor Presentation (February 2018)Investor deck36 slidesFeb 9, 2018
Investor Presentation (January 2018)Investor deck36 slidesJan 17, 2018
Investor Presentation (November 2017)Investor deck35 slidesNov 14, 2017
Investor Presentation (September 2017)Investor deck30 slidesSep 11, 2017
Investor Presentation (August 2017)Investor deck27 slidesAug 3, 2017
Investor Presentation (March 2017)Investor deck34 slidesMar 10, 2017
Investor Presentation (January 2017)Investor deck36 slidesJan 27, 2017
Investor Presentation (October 2016)Investor deck36 slidesOct 25, 2016
Investor Presentation (September 2016)Investor deck26 slidesSep 13, 2016
Investor Presentation (June 2016)Investor deck24 slidesJun 2, 2016
Investor Presentation (March 2016)Investor deck31 slidesMar 9, 2016
Investor Presentation (January 2016)Investor deck24 slidesJan 11, 2016
BIO Investor Conference 2015Conference20 slidesOct 20, 2015
Virtual Investor Conference August 2015Conference24 slidesAug 6, 2015

Open Decks

Financings

RaiseDate
Private placement of series B Convertible Preferred Stock
Closed: US$1M raised · US$2.2 a share
Buyers: affiliate of Eos SENOLYTIX, Inc.
Use of proceeds: Working capital and other general corporate purposes
Apr 21, 2026

Open Financings · Read by 6ix AI from the company's releases

IPO

Went public as Ruthigen, Inc. Priced at US$7.25 a unit on Mar 21, 2014.

Price
US$7.25 a unit
Units offered
2,650,000 units
Offering size
US$19.2 million
Underwriters' option
Up to 397,500 more units
Underwriter
Dawson James Securities, Inc.
Units delivered
On or about Mar 26, 2014

Steps

StepWhen
Draft sent to the SEC in confidenceMay 24, 2013
Filed publiclyAug 8, 2013
Amended 6 timesNewest Mar 12, 2014
Shares registered with an exchangeNov 13, 2013
Declared effective by the SECMar 21, 2014
Final prospectus, with the priceMar 21, 2014

Open IPO · From the cover of the final prospectus (424B4) filed Mar 21, 2014

Financials

Annual, in USD

Income statement

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue07.81M7.30M6.07M5.17M12.6M7.91M153.0K335.0K835.0K
Cost of revenue38.0K7.17M15.5M1.54M15.4M12.8M13.0M10.2M10.2M
Gross profit-38.0K640.0K-8.22M6.07M-10.2M12.6M-4.93M-12.8M-9.91M-9.32M
Research and development38.0K7.17M15.5M18.2M15.4M15.6M12.8M13.0M10.2M10.2M
Selling, general and administrative5.13M7.79M6.52M6.78M6.38M6.89M8.49M7.52M7.57M8.02M
Operating income-5.17M-9.76M-14.7M-18.9M-20.2M-9.86M-20.7M-20.4M-17.5M-24.9M
Depreciation and amortization0106.0K134.0K162.0K169.0K215.0K182.0K231.0K246.0K250.0K
EBITDA-5.17M-9.66M-14.6M-18.8M-20.0M-9.65M-20.5M-20.2M-17.2M-24.6M
Interest expense111.0K4.00K0186.0K186.0K643.0K881.0K
Income before tax-5.16M-9.56M-14.1M-18.8M-20.2M-19.3M-20.6M-20.6M-18.1M-30.8M
Income tax0-9.56M1.31M-111.0K2.33M9.21M68.0K68.0K-62.0K-2.96M
Net income-5.16M-9.56M-14.1M-18.8M-20.2M-19.3M-20.6M-20.6M-18.1M-27.8M
Earnings per share, basic-1.41-2.62-3.87-5.46-8.63-13.43-1.23-4.98-9.32-1.88
Earnings per share, diluted-1.41-2.62-3.87-5.46-8.63-13.43-1.23-4.98-9.32-1.88

Balance sheet

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash and equivalents4.09M9.52M19.2M35.6M53.8M31.7M23.4M2.56M3.55M4.18M
Short-term investments00
Receivables0928.0K1.30M67.0K84.0K7.20M01.00K206.0K
Inventory-370.0K153.0K1667.0K556.0K00
Current assets4.13M9.92M20.8M38.1M54.8M32.5M31.4M3.28M4.25M4.76M
Property, plant and equipment1.16M235.0K321.0K361.0K270.0K394.0K614.0K786.0K
Goodwill03.58M3.58M10.8M10.9M10.9M
Total assets4.14M9.94M34.0M41.0M58.8M38.1M36.1M14.7M16.0M16.7M
Accounts payable272.0K809.0K1.92M1.19M839.0K851.0K600.0K1.18M457.0K747.0K
Current liabilities329.0K929.0K3.91M5.02M4.44M8.18M17.2M2.88M5.84M4.65M
Long-term debt03.22M
Total debt8.76M857.0K2.29M1.74M675.0K03.22M5.80M
Total liabilities329.0K996.0K16.0M9.84M11.4M15.0M25.1M2.88M5.84M7.90M
Shareholders' equity3.81M8.95M18.0M31.1M47.4M23.1M11.0M11.8M10.1M8.76M
Shares outstanding3.65M3.65M3.65M3.64M3.22M1.81M20.0M4.92M2.10M14.9M

Cash flow

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash from operations-5.43M-10.7M-16.0M-19.4M-19.7M-12.5M3.23M-16.8M-14.5M-13.2M
Capital spending0-398.0K-676.0K-86.0K-144.0K-281.0K-58.0K-19.0K-74.0K-455.0K
Free cash flow-5.43M-11.1M-16.7M-19.4M-19.9M-12.8M3.17M-16.8M-14.6M-13.7M
Cash from investing-398.0K-676.0K-86.0K-144.0K-281.0K-58.0K-19.0K-74.0K-431.0K
Cash from financing053.0K1.23M43.5M21.0M17.7M15.8M13.9M-1.05M
Dividends paid-3.20M00
Share buybacks-152.0K21.0M17.7M19.3M16.6M0
Change in cash-5.43M-11.1M-16.6M-18.2M23.6M8.22M20.9M-987.0K-632.0K-14.7M

Open Financials

Filings

FilingDateTypeFiled with
8-K · Current reportNov 17, 2026ResultsSEC
10-Q · Quarterly reportNov 16, 2026Quarterly reportSEC
425Nov 9, 2026Other filingsSEC
425Oct 30, 2026Other filingsSEC
8-K · Current reportOct 27, 2026Meeting outcomeSEC
424B3 · ProspectusOct 26, 2026Offer documentSEC
EFFECT · Notice that a registration is effectiveOct 23, 2026Other filingsSEC
425Oct 22, 2026Other filingsSEC
425Oct 13, 2026Other filingsSEC
424B3 · ProspectusOct 7, 2026Offer documentSEC
Show 200 filings
FilingDateTypeFiled with
DEFA14A · Additional proxy materialOct 7, 2026Meeting noticeSEC
ARS · Annual report to shareholdersOct 5, 2026Annual reportSEC
S-3/A · Registration statement, amendedOct 2, 2026Offer documentSEC
EFFECT · Notice that a registration is effectiveSep 28, 2026Other filingsSEC
424B3 · ProspectusSep 25, 2026Offer documentSEC
DEFM14ASep 25, 2026Meeting noticeSEC
S-4/A · Registration statement, amendedSep 23, 2026Offer documentSEC
425Sep 22, 2026Other filingsSEC
S-4/A · Registration statement, amendedSep 17, 2026Offer documentSEC
S-4/A · Registration statement, amendedSep 4, 2026Offer documentSEC
10-Q · Quarterly reportAug 13, 2026Quarterly reportSEC
8-K · Current reportAug 13, 2026ResultsSEC
S-3/A · Registration statement, amendedAug 7, 2026Offer documentSEC
S-4/A · Registration statement, amendedAug 3, 2026Offer documentSEC
S-4 · Registration statementJul 9, 2026Offer documentSEC
10-K/A · Annual report, amendedJun 16, 2026Annual reportSEC
425Jun 5, 2026Other filingsSEC
S-3 · Registration statementJun 4, 2026Offer documentSEC
10-Q · Quarterly reportMay 15, 2026Quarterly reportSEC
8-K · Current reportMay 15, 2026ResultsSEC
DRS · Draft registration statementMay 14, 2026Offer documentSEC
SCHEDULE 13D · Big-stake noticeApr 22, 2026Big-stake noticeSEC
8-K · Current reportApr 21, 2026Current reportSEC
DApr 15, 2026Other filingsSEC
8-K · Current reportMar 27, 2026Material contractSEC
425Mar 26, 2026Other filingsSEC
8-K · Current reportMar 2, 2026Current reportSEC
10-K · Annual reportFeb 26, 2026Annual reportSEC
8-K · Current reportFeb 26, 2026ResultsSEC
8-K · Current reportDec 18, 2025Current reportSEC
10-Q · Quarterly reportOct 16, 2025Quarterly reportSEC
8-K · Current reportOct 16, 2025ResultsSEC
10-Q · Quarterly reportAug 6, 2025Quarterly reportSEC
8-K · Current reportAug 6, 2025ResultsSEC
425Jun 16, 2025Other filingsSEC
8-K · Current reportJun 16, 2025Meeting outcomeSEC
10-Q · Quarterly reportMay 15, 2025Quarterly reportSEC
8-K · Current reportMay 15, 2025Acquisition or disposalSEC
EFFECT · Notice that a registration is effectiveMay 12, 2025Other filingsSEC
424B3 · ProspectusMay 9, 2025Offer documentSEC
CORRESP · Letter to the SECMay 8, 2025Other filingsSEC
CORRESP · Letter to the SECMay 7, 2025Other filingsSEC
S-4/A · Registration statement, amendedMay 6, 2025Offer documentSEC
S-4/A · Registration statement, amendedApr 17, 2025Offer documentSEC
CORRESP · Letter to the SECApr 17, 2025Other filingsSEC
8-K · Current reportApr 10, 2025Material contractSEC
8-K · Current reportApr 8, 2025Meeting outcomeSEC
10-K · Annual reportMar 21, 2025Annual reportSEC
8-K · Current reportMar 21, 2025ResultsSEC
UPLOAD · Letter from the SECMar 17, 2025Other filingsSEC
S-4 · Registration statementFeb 14, 2025Offer documentSEC
8-K · Current reportFeb 14, 2025Current reportSEC
425Jan 22, 2025Other filingsSEC
8-K · Current reportDec 20, 2024Meeting outcomeSEC
8-K · Current reportNov 13, 2024Material contractSEC
ARS · Annual report to shareholdersNov 8, 2024Annual reportSEC
DEF 14A · Proxy statementNov 8, 2024Meeting noticeSEC
10-Q · Quarterly reportNov 8, 2024Quarterly reportSEC
8-K · Current reportNov 8, 2024ResultsSEC
8-K · Current reportOct 8, 2024Current reportSEC
10-Q · Quarterly reportAug 13, 2024Quarterly reportSEC
8-K · Current reportAug 13, 2024ResultsSEC
8-K · Current reportJul 19, 2024Management or board changeSEC
EFFECT · Notice that a registration is effectiveMay 31, 2024Other filingsSEC
8-K · Current reportMay 29, 2024Material contractSEC
CORRESP · Letter to the SECMay 28, 2024Other filingsSEC
UPLOAD · Letter from the SECMay 23, 2024Other filingsSEC
S-3 · Registration statementMay 17, 2024Offer documentSEC
8-K · Current reportMay 15, 2024Current reportSEC
10-Q · Quarterly reportMay 10, 2024Quarterly reportSEC
8-K · Current reportMay 10, 2024ResultsSEC
424B3 · ProspectusMar 28, 2024Offer documentSEC
10-K · Annual reportMar 28, 2024Annual reportSEC
8-K · Current reportMar 28, 2024ResultsSEC
8-K · Current reportMar 13, 2024Management or board changeSEC
8-K · Current reportMar 4, 2024Current reportSEC
8-K · Current reportJan 8, 2024ResultsSEC
SC 13G/A · Big-stake notice, amendedJan 2, 2024Big-stake noticeSEC
10-Q · Quarterly reportNov 9, 2023Quarterly reportSEC
8-K · Current reportNov 9, 2023ResultsSEC
10-Q · Quarterly reportAug 10, 2023Quarterly reportSEC
8-K · Current reportAug 10, 2023ResultsSEC
8-K · Current reportJul 13, 2023Meeting outcomeSEC
8-K · Current reportJul 11, 2023Current reportSEC
ARS · Annual report to shareholdersJun 2, 2023Annual reportSEC
DEF 14A · Proxy statementJun 2, 2023Meeting noticeSEC
10-Q · Quarterly reportMay 12, 2023Quarterly reportSEC
8-K · Current reportMay 12, 2023ResultsSEC
10-K · Annual reportMar 30, 2023Annual reportSEC
8-K · Current reportMar 30, 2023ResultsSEC
SC 13G/A · Big-stake notice, amendedFeb 8, 2023Big-stake noticeSEC
8-K · Current reportFeb 6, 2023Current reportSEC
8-K · Current reportFeb 3, 2023Current reportSEC
4 · Change in ownershipJan 30, 2023Insider tradeSEC
4 · Change in ownershipJan 30, 2023Insider tradeSEC
4 · Change in ownershipJan 30, 2023Insider tradeSEC
4 · Change in ownershipJan 30, 2023Insider tradeSEC
4 · Change in ownershipJan 30, 2023Insider tradeSEC
4 · Change in ownershipJan 30, 2023Insider tradeSEC
4 · Change in ownershipJan 30, 2023Insider tradeSEC
4 · Change in ownershipJan 30, 2023Insider tradeSEC
8-K · Current reportJan 25, 2023Current reportSEC
8-K · Current reportJan 11, 2023Current reportSEC
SC 13G/A · Big-stake notice, amendedJan 10, 2023Big-stake noticeSEC
8-K · Current reportJan 4, 2023Current reportSEC
8-K · Current reportNov 14, 2022ResultsSEC
10-Q · Quarterly reportNov 10, 2022Quarterly reportSEC
8-K · Current reportSep 26, 2022Current reportSEC
10-Q · Quarterly reportAug 10, 2022Quarterly reportSEC
8-K · Current reportAug 10, 2022ResultsSEC
424B3 · ProspectusAug 9, 2022Offer documentSEC
8-K · Current reportJul 12, 2022Current reportSEC
8-K · Current reportJun 15, 2022Meeting outcomeSEC
10-Q · Quarterly reportMay 12, 2022Quarterly reportSEC
8-K · Current reportMay 12, 2022ResultsSEC
DEFA14A · Additional proxy materialMay 2, 2022Meeting noticeSEC
DEF 14A · Proxy statementApr 29, 2022Meeting noticeSEC
8-K · Current reportApr 29, 2022Current reportSEC
3 · Initial statement of ownershipApr 19, 2022Insider tradeSEC
8-K · Current reportApr 15, 2022Management or board changeSEC
S-8 · Registration statement for employee plansMar 29, 2022Offer documentSEC
10-K · Annual reportMar 29, 2022Annual reportSEC
8-K · Current reportMar 29, 2022ResultsSEC
8-K · Current reportMar 21, 2022Current reportSEC
8-K · Current reportMar 17, 2022Current reportSEC
8-K · Current reportMar 4, 2022Current reportSEC
4 · Change in ownershipMar 3, 2022Insider tradeSEC
3 · Initial statement of ownershipMar 3, 2022Insider tradeSEC
8-K · Current reportFeb 24, 2022Current reportSEC
8-K · Current reportFeb 15, 2022Current reportSEC
SC 13G/A · Big-stake notice, amendedFeb 14, 2022Big-stake noticeSEC
8-K · Current reportFeb 11, 2022Meeting outcomeSEC
SC 13G/A · Big-stake notice, amendedFeb 11, 2022Big-stake noticeSEC
SC 13G/A · Big-stake notice, amendedFeb 10, 2022Big-stake noticeSEC
DEFA14A · Additional proxy materialFeb 1, 2022Meeting noticeSEC
4 · Change in ownershipJan 31, 2022Insider tradeSEC
4 · Change in ownershipJan 31, 2022Insider tradeSEC
4 · Change in ownershipJan 31, 2022Insider tradeSEC
4 · Change in ownershipJan 28, 2022Insider tradeSEC
4 · Change in ownershipJan 28, 2022Insider tradeSEC
4 · Change in ownershipJan 28, 2022Insider tradeSEC
4 · Change in ownershipJan 28, 2022Insider tradeSEC
SC 13G/A · Big-stake notice, amendedJan 5, 2022Big-stake noticeSEC
DEFA14A · Additional proxy materialDec 30, 2021Meeting noticeSEC
DEF 14A · Proxy statementDec 30, 2021Meeting noticeSEC
PRE 14A · Preliminary proxy statementDec 20, 2021Meeting noticeSEC
DEFA14A · Additional proxy materialDec 17, 2021Meeting noticeSEC
8-K · Current reportDec 17, 2021Current reportSEC
424B5 · ProspectusDec 17, 2021Offer documentSEC
DEFA14A · Additional proxy materialDec 17, 2021Meeting noticeSEC
8-K/A · Current report, amendedDec 17, 2021Material contractSEC
DEFA14A · Additional proxy materialDec 15, 2021Meeting noticeSEC
8-K · Current reportDec 15, 2021Material contractSEC
8-K · Current reportDec 7, 2021Current reportSEC
10-Q · Quarterly reportNov 10, 2021Quarterly reportSEC
8-K · Current reportNov 10, 2021ResultsSEC
8-K · Current reportNov 9, 2021Material contractSEC
8-K · Current reportAug 23, 2021Current reportSEC
10-Q · Quarterly reportAug 10, 2021Quarterly reportSEC
8-K · Current reportAug 10, 2021ResultsSEC
4 · Change in ownershipJul 28, 2021Insider tradeSEC
3 · Initial statement of ownershipJul 28, 2021Insider tradeSEC
8-K · Current reportJul 27, 2021Management or board changeSEC
DJul 20, 2021Other filingsSEC
8-K · Current reportJun 17, 2021Meeting outcomeSEC
8-K · Current reportJun 16, 2021Current reportSEC
EFFECT · Notice that a registration is effectiveJun 10, 2021Other filingsSEC
CORRESP · Letter to the SECJun 7, 2021Other filingsSEC
UPLOAD · Letter from the SECJun 7, 2021Other filingsSEC
S-3 · Registration statementMay 26, 2021Offer documentSEC
10-K/A · Annual report, amendedMay 14, 2021Annual reportSEC
8-K · Current reportMay 13, 2021Current reportSEC
10-Q · Quarterly reportMay 11, 2021Quarterly reportSEC
8-K · Current reportMay 11, 2021ResultsSEC
8-K · Current reportMay 10, 2021Current reportSEC
DEF 14A · Proxy statementApr 29, 2021Meeting noticeSEC
DEFA14A · Additional proxy materialApr 29, 2021Meeting noticeSEC
8-K/A · Current report, amendedApr 13, 2021Current reportSEC
8-K · Current reportApr 12, 2021Current reportSEC
8-K · Current reportApr 5, 2021Management or board changeSEC
10-K/A · Annual report, amendedMar 26, 2021Annual reportSEC
10-K · Annual reportMar 23, 2021Annual reportSEC
8-K · Current reportMar 23, 2021ResultsSEC
8-K · Current reportMar 4, 2021Current reportSEC
SC 13D · Big-stake noticeFeb 25, 2021Big-stake noticeSEC
SC 13G · Big-stake noticeFeb 24, 2021Big-stake noticeSEC
DFeb 23, 2021Other filingsSEC
8-K · Current reportFeb 16, 2021Material contractSEC
SC 13G/A · Big-stake notice, amendedFeb 16, 2021Big-stake noticeSEC
424B5 · ProspectusFeb 16, 2021Offer documentSEC

This page holds 200 of 655 filings. Open Filings

Open Filings · All of its filings on SEC EDGAR

Cap table

Built by 6ix from Pulmatrix, Inc.’s releases · as of Nov 12, 2026

Common shares
3,652,285
Fully diluted
3,652,285

Fully diluted

LineSharesAs of
Common shares3,652,285Nov 12, 2026

Share count over time

CountShares
Nov 12, 20263,652,285
Sep 30, 20263,652,285

Open Cap table

Shareholders

Institutions

HolderSharesOf the companyValueAs of
Renaissance Technologies120K3.3%US$183KSep 30, 2026
BlackRock54,8991.5%US$83,446Sep 30, 2026
Vanguard47,0091.3%US$71,454Sep 30, 2026
Shay Capital LLC33,9580.93%US$51,616Sep 30, 2026
Geode Capital33,2020.91%US$50,489Sep 30, 2026
SBI Securities Co., Ltd.30,1650.83%US$45,851Sep 30, 2026
Susquehanna14,2520.39%US$21,663Sep 30, 2026
State Street13,9450.38%US$21,196Sep 30, 2026
Virtu Financial LLC13,7220.38%US$21,000Sep 30, 2026
UBS10<0.01%US$15Sep 30, 2026
All 15 holders
HolderSharesOf the companyValueAs of
RBC7<0.01%Sep 30, 2026
Farther Finance Advisors, LLC7<0.01%US$11Sep 30, 2026
Barclays4<0.01%US$7Sep 30, 2026
Allworth Financial LP3<0.01%US$5Sep 30, 2026
Northwestern Mutual Wealth Management Co1<0.01%US$2Sep 30, 2026

Funds

HolderSharesOf the companyValueAs of
Vanguard Extended Market Index Fund32,2940.88%US$54,900Jun 30, 2026
Fidelity Extended Market Index Fund23,0140.63%US$31,989May 31, 2026
Fidelity Series Total Market Index Fund5,2280.14%US$7,267May 31, 2026
Fidelity Nasdaq Composite Index Fund4,5700.13%US$6,352May 31, 2026
Fidelity Total Market Index Fund4,4270.12%US$6,154May 31, 2026

Big stakes

StakeStakeSharesDateFiling
RCM Eos PIPE HOLDINGS, LLC9.99%405KApr 16, 2026Schedule 13D

Open Shareholders

People

6ix reads each seat by machine from the page it links to, and can misread one.

PersonSeat
Terrance McGuire
Other companies: Tectonic Therapeutic, Inc. (Director · Since at least Jun 20, 2024); Invivyd, Inc. (Director · Since at least Aug 5, 2021); Seer, Inc. (Director · Since at least Dec 3, 2020); Cyclerion Therapeutics, Inc. (Director · Apr 1, 2019 – Nov 30, 2023 · Past); Alector, Inc. (Director · Feb 6, 2019 – Sep 11, 2023 · Past); X4 Pharmaceuticals, Inc. (Director · Nov 15, 2017 – Jun 5, 2018 · Past); Trevena, Inc. (Director · Jan 30, 2014 – May 14, 2014 · Past); Acceleron Pharma Inc (Director · Sep 18, 2013 – Mar 2, 2017 · Past); Ironwood Pharmaceuticals, Inc. (Director · Jun 3, 2013 – Apr 1, 2019 · Past)
Director · Jun 15, 2015 – May 16, 2019 · Past
Mark Iwicki
Other companies: Inhibikase Therapeutics, Inc. (Chief Executive Officer - Inhibikase · Since at least Feb 14, 2025); Q32 Bio Inc. (Director · Since at least Mar 25, 2024); Third Harmonic Bio Inc. (Director · Since at least Sep 14, 2022); Akero Therapeutics Inc (Director · Since at least Jun 19, 2019); Kala Bio, Inc. (Director · Since at least Jul 19, 2017); Jade Biosciences, Inc. (Director · Apr 2, 2021 – Jun 5, 2024 · Past); Aimmune Therapeutics Inc (Director · May 25, 2016 – Oct 10, 2020 · Past)
Director · Mar 20, 2017 – Jan 28, 2021 · Past
Steven Gillis
Other companies: Kardigan, Inc. (Director · Since at least Jun 22, 2026); Takeda Pharmaceutical Co. Ltd. (Director · Since at least Mar 18, 2026); Metsera, Inc. (Director · Since at least Nov 13, 2025); Codiak BioSciences Inc (Director · Oct 13, 2020 – Feb 16, 2023 · Past); VBI Vaccines Inc. (Director · Jun 14, 2019 – Jul 27, 2023 · Past); Q32 Bio Inc. (Director · Jun 6, 2019 – Jun 14, 2023 · Past)
Director · May 16, 2019 – Aug 28, 2020 · Past
Scott M Rocklage
Other companies: Aprea Therapeutics, Inc. (Director · Oct 2, 2019 – Jun 30, 2020 · Past); Cidara Therapeutics Inc (Director · Apr 14, 2015 – Jun 13, 2018 · Past); EPIRUS Biopharmaceuticals Inc (Director · Jul 15, 2014 – Jun 5, 2015 · Past); Achaogen Inc (Director · Mar 11, 2014 – Mar 11, 2014 · Past); Relypsa Inc (Director · Nov 14, 2013 – Nov 20, 2013 · Past)
Director · Jun 15, 2015 – Feb 3, 2016 · Past
Michael J. Higgins
Other companies: CAMP4 Therapeutics Corporation (Director · Since at least Oct 10, 2024); Voyager Therapeutics, Inc. (Chair · Since at least Nov 10, 2015); Cyclerion Therapeutics, Inc. (Director · Nov 30, 2023 – Mar 25, 2025 · Past); Ironwood Pharmaceuticals, Inc. (Chief Operating Officer · Feb 2, 2010 – Dec 23, 2014 · Past)
Chairman of the PULMATRiX Board of Directors · Since at least Jun 15, 2015
Anand VaradanSince at least Nov 4, 2026
Chris Cabell MDSenior Vice President, Head of Clinical Development · Since at least Nov 4, 2026
Margaret WasilewskiChief Medical Officer · Mar 1, 2022 – Jan 26, 2023 · Past
Michelle SiegertVice President, Finance · Nov 13, 2019 – Jan 26, 2023 · Past
Peter LudlumInterim Chief Executive Officer · Since at least Aug 13, 2026
All 14 people
PersonSeat
Rick BatyckyChief Executive Officer · Since at least Nov 4, 2026
Sameer HarishChief Financial Officer · Mar 21, 2014 – May 11, 2014 · Past
Teofilo David RaadChief Executive Officer, Director · Jun 5, 2018 – Jan 26, 2023 · Past
Todd BazemoreChief Operating Officer · Since at least Nov 4, 2026

Open People

Log in to ask 6ix AI your own questions about Pulmatrix, Inc.